1. Home
  2. AVIR vs NAKA Comparison

AVIR vs NAKA Comparison

Compare AVIR & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVIR
  • NAKA
  • Stock Information
  • Founded
  • AVIR 2012
  • NAKA 2019
  • Country
  • AVIR United States
  • NAKA United States
  • Employees
  • AVIR N/A
  • NAKA N/A
  • Industry
  • AVIR Medicinal Chemicals and Botanical Products
  • NAKA
  • Sector
  • AVIR Health Care
  • NAKA
  • Exchange
  • AVIR Nasdaq
  • NAKA Nasdaq
  • Market Cap
  • AVIR 290.4M
  • NAKA 347.4M
  • IPO Year
  • AVIR 2020
  • NAKA 2024
  • Fundamental
  • Price
  • AVIR $3.25
  • NAKA $0.72
  • Analyst Decision
  • AVIR Hold
  • NAKA Strong Buy
  • Analyst Count
  • AVIR 1
  • NAKA 2
  • Target Price
  • AVIR $6.00
  • NAKA $5.00
  • AVG Volume (30 Days)
  • AVIR 353.8K
  • NAKA 31.9M
  • Earning Date
  • AVIR 11-12-2025
  • NAKA 11-05-2025
  • Dividend Yield
  • AVIR N/A
  • NAKA N/A
  • EPS Growth
  • AVIR N/A
  • NAKA N/A
  • EPS
  • AVIR N/A
  • NAKA N/A
  • Revenue
  • AVIR N/A
  • NAKA $2,239,936.00
  • Revenue This Year
  • AVIR N/A
  • NAKA N/A
  • Revenue Next Year
  • AVIR N/A
  • NAKA $2,755.19
  • P/E Ratio
  • AVIR N/A
  • NAKA N/A
  • Revenue Growth
  • AVIR N/A
  • NAKA N/A
  • 52 Week Low
  • AVIR $2.46
  • NAKA $0.65
  • 52 Week High
  • AVIR $4.02
  • NAKA $34.77
  • Technical
  • Relative Strength Index (RSI)
  • AVIR 55.27
  • NAKA 32.70
  • Support Level
  • AVIR $3.18
  • NAKA $0.78
  • Resistance Level
  • AVIR $3.27
  • NAKA $0.98
  • Average True Range (ATR)
  • AVIR 0.09
  • NAKA 0.10
  • MACD
  • AVIR 0.00
  • NAKA 0.14
  • Stochastic Oscillator
  • AVIR 60.00
  • NAKA 8.15

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: